- Home
- CLCO vs RIGL Comparison
CLCO vs RIGL Comparison
Compare CLCO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLCO | RIGL |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.5M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CLCO | RIGL |
|---|---|---|
| Price | $9.79 | $42.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | 247.9K | ★ 529.1K |
| Earning Date | 11-20-2025 | 11-04-2025 |
| Dividend Yield | ★ 6.07% | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 1.12 | ★ 6.20 |
| Revenue | ★ $327,762,000.00 | $282,076,000.00 |
| Revenue This Year | $4.24 | $65.53 |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | $8.86 | ★ $6.95 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $4.51 | $15.50 |
| 52 Week High | $10.00 | $52.24 |
Technical Indicators
Market Signals| Indicator | CLCO | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 49.52 |
| Support Level | $9.80 | $40.52 |
| Resistance Level | $10.00 | $44.85 |
| Average True Range (ATR) | 0.06 | 1.79 |
| MACD | -0.01 | -0.31 |
| Stochastic Oscillator | 20.37 | 47.46 |
Price Performance
Historical ComparisonAbout CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.